Revenue from Contracts with Customers (Tables)

3 Months Ended

Mar. 31, 2019

Schedule of Manufacturing and Royalty Revenues

During the three months ended March 31, 2019 and 2018, the Company recorded manufacturing and royalty revenues as follows:

	Three Months Ended March 31, 2019
(In thousands)	Manufacturing Revenue		Royalty Revenue		Total
INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA	$	—	$	53,298	$	53,298
RISPERDAL CONSTA		17,921		4,385		22,306
AMPYRA/FAMPYRA		5,680		6,506		12,186
Other		7,346		13,779		21,125
	$	30,947	$	77,968	$	108,915

	Three Months Ended March 31, 2018
(In thousands)	Manufacturing Revenue		Royalty Revenue		Total
INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA	$	—	$	46,086	$	46,086
AMPYRA/FAMPYRA		13,563		14,696		28,259
RISPERDAL CONSTA		17,792		4,912		22,704
Other		6,236		11,316		17,552
	$	37,591	$	77,010	$	114,601

Schedule of Contract Assets and Contract Liabilities

Contract assets consisted of the following:

(In thousands)	Contract Assets
Contract assets at January 1, 2019	$	8,230
Additions		7,346
Transferred to receivables, net		(7,129	)
Contract assets at March 31, 2019	$	8,447

Contract Liabilities—Contract liabilities consist of contractual obligations related to deferred revenue.

Contract liabilities consisted of the following:

(In thousands)	Contract Liabilities
Contract liabilities at January 1, 2019	$	12,694
Additions		1,516
Amounts recognized into revenue		(790	)
Contract liabilities at March 31, 2019	$	13,420

Product sales, net

Schedule of Disaggregation of Revenue

During the three months ended March 31, 2019 and 2018, the Company recorded product sales, net, as follows:

	Three Months Ended March 31,
(In thousands)	2019		2018
VIVITROL	$	69,183	$	62,682
ARISTADA		30,298		29,160
Total product sales, net	$	99,481	$	91,842